Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty L | DMSO
SGLT Inhibitors
Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, in overweight/obese patients with type 1 diabetes: addressing unmet needs as adjunct therapy to insulin - Media Centre | EASD
Clinical Significance Of SGLT-2 | Our Biochemistry- Namrata Chhabra
Development of SGLT1 and SGLT2 inhibitors | SpringerLink
Kidney and Dialysis | Free Full-Text | The Pathophysiological Basis of Diabetic Kidney Protection by Inhibition of SGLT2 and SGLT1
The role of SGLT2 inhibitors in Type 2 Diabetes - Pavilion Health Today
Structural mechanism of SGLT1 inhibitors | Nature Communications
PharmaWiki - SGLT2-Hemmer
Frontiers | New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure
Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus. - Abstract - Europe PMC
Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care | Diabetes Technology & Therapeutics
24-week efficacy and safety of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes (inTandem2) - Media Centre | EASD
Lexicon Fires Back after Sanofi Ends Up-to-$1.7B Diabetes Collaboration
Sodium–glucose cotransporters: Functional properties and pharmaceutical potential - Sano - 2020 - Journal of Diabetes Investigation - Wiley Online Library
Typ-1-Diabetes
Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus. - Abstract - Europe PMC
Antidiabetic Effects of a Tripeptide That Decreases Abundance of Na+-d-glucose Cotransporter SGLT1 in the Brush-Border Membrane of the Small Intestine | ACS Omega
Carbohydrates in medicines (SGLT-2 inhibitors for the treatment of type 2 diabetes mellitus)
SGLT inhibitors in management of diabetes - The Lancet Diabetes & Endocrinology
Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials | The BMJ
SGLT2 Inhibitors – Diabetologia
The Na+‐D‐glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer | Semantic Scholar
